The U.S. Food and Drug Administration has approved Medtronic's deep brain stimulation system for use in patients with ...

The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

Medtronic ( MDT 2.27%) and Johnson & Johnson ( JNJ 1.64%) are two very healthy, high-yielding dividend stocks. This makes ...

The BrainSense Adaptive technology is an enhancement to Medtronic’s Percept DBS neurostimulators. The advancement personalizes therapy based on a patient’s brain activity in real-time. Therapy ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Medtronic on Tuesday missed Wall Street estimates for third-quarter revenue due to lower purchases of its surgical devices by ...

Medtronic said the Food and Drug Administration approved a brain stimulation system for people afflicted with Parkinson's disease.

The company's adaptive deep brain stimulation technology for Parkinson's disease therapy is expected to be available nationwide in the next few months.

Jeff Jonas, portfolio manager at Gabelli Funds, said he’s surprised at the drop in Medtronic’s stock on the heels of its ...

Shares of Medtronic ( MDT -6.63%) were sinking 7.3% as of 11:21 a.m. ET on Tuesday. The decline came after the medical device ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no ...